Shufro Rose & Co’s PDL BioPharma, Inc. PDLI Stock Holding History

Shufro Rose & Co’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,000	Closed	-$32K	–	331
2019 Q4	$32K	Hold	10,000	–	–	﹤0.01%	311
2019 Q3	$22K	Hold	10,000	–	–	﹤0.01%	324
2019 Q2	$31K	Hold	10,000	–	–	﹤0.01%	300
2019 Q1	$37K	Sell	10,000 -1,500	-13%	-$5.06K	﹤0.01%	291
2018 Q4	$33K	Hold	11,500	–	–	﹤0.01%	290
2018 Q3	$30K	Hold	11,500	–	–	﹤0.01%	292
2018 Q2	$27K	Hold	11,500	–	–	﹤0.01%	295
2018 Q1	$34K	Hold	11,500	–	–	﹤0.01%	299
2017 Q4	$32K	Hold	11,500	–	–	﹤0.01%	285
2017 Q3	$39K	Hold	11,500	–	–	﹤0.01%	286
2017 Q2	$28K	Hold	11,500	–	–	﹤0.01%	265
2017 Q1	$26K	Buy	+11,500	New	+$25.4K	﹤0.01%	270

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Shufro Rose & Co's PDLI Position: Q1 2020 in Review

Shufro Rose & Co sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 10,000 shares — an estimated $32K sold.

Shufro Rose & Co first reported a position in PDLI in Q1 2017 and held it in 12 quarters. The position peaked at $39K in Q3 2017. 132 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

Shufro Rose & Co reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
Shufro Rose & Co sold 10,000 PDL BioPharma, Inc. shares in Q1 2020, an estimated $32K.
Shufro Rose & Co first reported a position in PDL BioPharma, Inc. in Q1 2017 and held it in 12 quarters.
Shufro Rose & Co's PDL BioPharma, Inc. position peaked at $39K in Q3 2017.
132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on Shufro Rose & Co's 13F filing for Q1 2020, filed 22 Apr 2020.